Use of trimethazine in preparation of drugs for preventing and treating liver diseases

Abstract

Disclosed is a use of trimethazine in the preparation of drugs for preventing and treating liver diseases. Trimethazine is capable of inhibiting activation of resting T-cells to activated lymphocytes, reducing release of cytokines, and reducing hepatocyte injury caused by immune system; inhibiting fatty acid metabolism in hepatocytes, and optimizing the energy process in hepatocytes; and maintaining normal function of mitochondrial permeability transition pores, and reducing hepatocyte apoptosis. Trimethazine has the efficacy of maintaining the liver functions, and reducing transminase (comprising glutamic pyruvic transaminase, glutamic oxalacetic transaminase, etc.).

Description

TECHNICAL FIELD[0001]The present invention relates to new use of drugs, specifically a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases.BACKGROUND TECHNOLOGY[0002]Trimetazidine hydrochloride (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) has been used mainly in prevention and treatment of angina pectoris for a long time. It is a miscellaneous cardiovascular drug against angina pectoris, characterized in that TMZ prevents the ATP level in cells from decreasing by maintaining proper energy metabolism of cells in a hypoxic or ischemic state, thereby guaranteeing normal functioning of the ion pump and normal operation of the transmembrane sodium-potassium flow and maintaining a stable internal environment of cells. Therefore, it is an effective drug against myocardial ischemia.[0003]Liver-protection drug refers to the category of drugs used to protect liver functions, characterized in that it is capable of maintaining liver funct...

AI Technical Summary

Benefits of technology

The patent describes a drug called trimetazidine that has potential hepatoprotective benefits. It can reduce damage to liver cells caused by the immune system, inhibit fatty acid metabolism, and maintain the function of mitochondrial permeability transition pores. The drug is safe and well-tolerated, with minimal liver toxicity. It is mainly eliminated through urine without hepatic metabolism, and no serious adverse reaction was observed during clinical trials.

Problems solved by technology

At present, there is a shortage of large scale evidence-based medicine and action target researches on hepatoprotective drugs.

There are a great variety of existing hepatoprotective drugs, but all with single or unidentified sites of action and relatively limited “hepatoprotective” effects.

Since most drugs, not excluding most hepatoprotective drugs, are metabolized by liver, it increases the burden of the liver, which is remarkable in patients suffering from liver failure.

For example, all liver diseases caused by virus, drugs, alcohol, non-alcoholic fatty liver or autoimmunity or genetic and metabolic liver diseases can result in liver failure.

In recent years, liver failure is treated mainly through combined treatment, by preventing and treating all sorts of clinical complications, delaying hepatocyte injury and waiting for hepatocyte regeneration, but there is no effective drug to treat the liver failure induced by various liver diseases.

Images